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ABSTRACT 
A peptide (J14) containing conformationally restricted epitopes from the M protein of group A streptococcus (GAS) is 
capable of eliciting protective immune response against GAS infection. However, the protective response may be lost 
possibly due to its weak secondary-structure when the antigen is fused with other antigens in a recombinant polyepitope 
vaccine construct. We previously showed that JJo, a conformationally stabilized derivative of dimeric J14, overcomes 
this problem. We now show that anti JJo antibodies react with diverse GAS isolates found in the Indian sub-continent 
and that these antibodies are opsonic for GAS. The GAS strains used in this study were isolated from throat and skin 
swabs from Mumbai, Chennai and Vellore. Sera from mice immunized with recombinant JJo peptide were tested by 
ELISA, immunofluorescence, flow-cytometry, indirect bactericidal assay and mouse challenge assays to determine spe- 
cific immunogenicity, opsonic functions and protection against an Indian isolate. We propose that JJo is a robust anti- 
gen suitable for inclusion in recombinant multi-epitope vaccines which are potentially affordable option for the pediat- 
ric population of developing countries. 
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1. Introduction 
The human pathogen Streptococcus pyogenes, commonly 
referred to as group A streptococcus (GAS), causes a 
wide variety of diseases. These include mild upper res- 
piratory and skin infections, the incidences of which are 
very high among school going children, as well as severe 
invasive diseases such as necrotizing fasciitis and toxic 
shock syndrome and the post-infectious sequelae-rheu- 
matic fever (RF) and rheumatic heart disease (RHD) [1]. 
Although the incidence of RF and RHD has declined in 
many parts of the world, they continue to be a major 
cause of cardiovascular morbidity and mortality in 
developing countries [2,3]. This is particularly evident 
in India, where it is estimated that 600,000 children <15 
years of age suffer from RHD [3]. RF and RHD are auto- 
immune diseases and the M protein, a major strepto- 
coccal virulence factor, has been implicated in their pa- 
thogenesis. The M protein is also responsible for type- 
specific immunity against GAS [4]. Therefore, this 
protein has been a major target for vaccine design. 
For most parts, M protein is a coiled coil protein which 
contains a number of internal repeat sequences (A, B and 
C repeats) [5]. The amino terminus is highly poly- 
morphic and is the basis for typing while the carboxyl 
terminus including the C-repeat region (CRR) is highly 
conserved among GAS isolates [5]. Comprehensive 
dissection of the CRR has resulted in the identification of 
protective opsonic B cell epitopes that are void of cross 
reactive B- and T-cell epitopes; hence these B cell epi- 
topes are regarded as safe vaccine candidates [6]. These 
peptides however, are conformationally restricted. To 
help maintain their alpha helical conformation, an attri- 
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bute necessary for inducing a protective immune res- 
ponse, they are embedded within a short heterologous 
coil-promoting amino acid sequence. One such resulting 
chimeric peptide antigen is called J14 [7]. 
When conjugated to diphtheria toxoid, J14 elicits an 
immune response that reacts against multiple M types [8]. 
However, to date the efficacy of J14 has largely been 
shown against commonly circulating strains in developed 
countries [9]. In order to target vaccines to populations 
with high GAS disease burden and a large diversity of 
circulating GAS strains, such as populations of the Indian 
subcontinent, it is necessary to demonstrate that a va- 
ccine is effective in controlling local strains. In addition 
to broad cross reactivity, a vaccine that would make the 
most impact in such communities would also need to be 
affordable. In an attempt to address this, we have ex- 
pressed J14 as a recombinant protein [10].  
When designing recombinant polyepitope vaccines con- 
taining J14 as one of the antigens, we and others [10,11] 
found that the immune responses to J14 moiety in the 
recombinant fusion proteins was poor while the other 
antigens elicited expected responses. We reasoned that 
the molecular forces required to present J14 in coiled coil 
conformation may be weak, and hence could be sensitive 
to the context of its fusion partner(s) in recombinant 
polyepitope constructs. To overcome this limitation we 
designed JJo, a dimer of J14 with continuous heptad 
repeat to strengthen its coil-promoting propensity [10]. 
JJo is immunogenic in the mouse model and can induce 
antibody response that recognizes the original vaccine 
antigen peptide J14 as well as the native M protein [10]. 
However, JJo has never been tested for the ability to 
stimulate an immune response that reacts against diverse 
GAS strains. Since binding of antibodies to the surface of 
GAS is a prerequisite for opsonisation, in the present 
work we used immunofluorescence and flow cytometry 
to screen a number of GAS isolates belonging to major 
Indian M types for their ability to bind antibodies raised 
against JJo as a first step toward vaccine efficacy test. 
We further show that the JJo antibodies are functional 
and can kill GAS in an opsonophagocytosis assay and 
offer protection against systemic GAS infection in a 
mouse model. 
2. Materials and Methods 
2.1. GAS Isolates and Microbiological Methods 
The GAS strains used in this study were isolated from 
throat or skin swabs as part of community survey in 
Mumbai, Chennai and Vellore. The strains were main- 
tained in Todd-Hewitt broth (THB) supplemented with 
10% glycerol (v/v) at −80˚C until used. All GAS isolates 
were typed using standard emm-sequencing protocols 
[12]. GAS C28 and Mu3 represented emm 63.3 and 81.2 
two major emm types among our collection of GAS iso- 
lates used in this study. PL1 an Australian isolate [13] 
and JRS145, an M-negative strain [14] were used for 
comparisons where appropriate. 
2.2. Protein Expression and Purification  
Recombinant JJo was expressed and purified as des- 
cribed before [10]. Briefly, recombinant JJo was purified 
from E. coli cellular fractions by Nickel ion affinity chro- 
matography. JJo expression was induced with 0.5 mM 
IPTG and subsequently purified under native conditions. 
The E. coli cell pellet was incubated for 30 minutes in 
lysis buffer (10mM Imidazole) containing 1 mM phenyl- 
methylsulphonyl fluoride (PMSF) and lysozyme (1 mg/ml) 
to promote cell lysis. The clarified cell lysate was passed 
through Ni-NTA resin pre-equilibriated with ice-cold 
lysis buffer, the column was washed five times with 
wash buffer (50 mM imidazole) and JJo protein was 
subsequently eluted with elution buffer (500 mM imi- 
dazole). Fractions containing JJo were pooled and dialy- 
zed against 2 L of phosphate buffer saline at 4˚C for 20 h 
with two buffer changes. 
2.3. Murine Immunization and Challenge Model 
To assess whether the recombinant vaccine candidate JJo 
could stimulate an antibody response against the parent 
peptide (J14) in mice of different genetic backgrounds, 
we determined the immunogenicity of purified JJo in 
Balb/c, C3HeJ and B10BR mice following methods 
previously described [8]. In addition, antibodies were 
also raised in Quackenbush mice to assess functionality 
in an out bred strain. All animal experiments were 
carried out in accordance with Indian Institute of Science 
(IISc) Animal Ethics Committee. On day 0, six week old 
female BALB/c, B10Br, C3HeJ or Quackenbush mice (n 
= 10) as detailed in the results received 30 μg of antigen 
emulsified with complete Freund’s adjuvant (CFA), at 
the base of the tail. Mice received boosts with 15 μg of 
antigen in PBS, on days 21, 28 and 35 unless otherwise 
specified. Blood samples (10 μl) were taken before each 
immunisation via a snip at the end of the tail, on days 0, 
20, 27 and 34. A full tail bleed (~200 μl) was taken 7 
days after the final boost on day 42. The antibody re- 
sponses in individual mice of the same genetic back- 
ground were quantified by ELISA as described earlier [8]. 
Whole cell ELISAs were also carried out with sera from 
Balb/c and C3HeJ immunised mice [15]. Endpoint anti- 
body titre was determined as the lowest dilution that had 
an absorbance higher than that of the average plus three 
standard deviations of the sham control serum. The sera 
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from mice of the same genetic background were sub- 
sequently pooled for further studies. 
On day 50, C3HeJ mice were challenged intraperito- 
neally with a pre-determined minimal lethal dose, fol- 
lowing previously described methods [16]. To enhance 
virulence for these experiments, GAS isolates were se- 
rially passaged several times in mice [17]. However, 
among the major Indian GAS strains in our collection, 
only Mu3 showed increased virulence in our model. 
Following challenge with Mu3 (400 μl of 108 cfu/ml), 
mice were observed daily for 10 days to monitor survival. 
Appropriate sham controls (mice immunized with CFA 
in PBS only) were included. 
2.4. Immunofluorescence and Flow-Cytometry 
For immunofluorescence, GAS strains grown overnight 
in 5 ml of THB/1% neopeptone at 37˚C, were collected 
and resuspended in PBS to an OD600 of 0.1. Twenty 
microlitres of bacterial suspension was smeared and 
fixed on poly-lysine microscopic slides with 3% para- 
formaldehyde. Fixed bacterial cells were blocked with 
5% skim milk in PBS-Tween 20 for 1 h in a humid 
chamber at 37˚C, then rinsed in PBS. Any cell-surface Fc 
receptors were subsequently blocked with purified non- 
specific polyclonal human IgG (Sigma, 1:200) for 1 h at 
37˚C. Blocked slides were incubated with anti-JJo or 
sham control (CFA in PBS vaccinated) mouse serum 
(1:50 dilution; Balb/C). The bound antibody was de- 
tected with fluorescein isothiocyanate (FITC)-conjugated 
secondary antibody (anti mouse-IgG) (Sigma, USA, 
1:200). JRS145, an M-negative mutant was used as a 
control. Slides were visualized at 520 nm under a 
confocal microscope (LSM-510 meta, Zeiss). The cell 
suspensions prepared for immunofluorescence were also 
processed in parallel for flow cytometric analysis as 
described earlier [8] with slight modifications. Cells were 
blocked with 3% bovine serum albumin (BSA) and 
human IgG prior to incubation with pooled anti-JJo or 
sham control serum (1:50 dilution). Cells with bound 
antibodies, were detected with anti-mouse IgG-FITC 
conjugated secondary antibody (Sigma, USA,) and sub- 
sequently counted using FACS Calibur flow cytometer 
(B&D, USA). CellQuest program was used to analyze 
the data. 
2.5. Indirect Bactericidal Assay 
Bactericidal assays were performed as described pre- 
viously [16], GAS isolates were cultured overnight in 
Todd-Hewitt broth at 37˚C. Fifty μl of the diluted culture 
(105) were mixed with 50 μl of serum (normal or immune 
serum from B10BR, Quackenbush and C3HeJ mice) and 
then the mixture was incubated for 3 hrs at 37˚C with 
end-over-end mixing with 400 μl of non-opsonic human 
blood which supports growths of GAS by > 32 times [17]. 
Subsequently 50 μl aliquots of this mixture were plated 
in duplicate using the pour plate method. Based on our 
previous calibrations GAS culture of a 105 dilution con- 
sistently gave 50 - 100 cfu in 50 μl. CFUs were count- ed 
after 24 h of incubation at 37˚C. Fifty microliters of the 
bacterial dilution were also plated likewise to confirm the 
size of the inoculum. Bactericidal activity of immune 
sera (% reduction in mean CFU) was calculated as: 1 – 
[mean CFUs in the presence of immune mouse sera/ 
mean CFUs in the presence of sera from PBS immunised 
mice] × 100. Each sample was tested in duplicate. 
3. Results 
3.1. Characterization of Antibody Response to  
JJo 
Earlier studies [16] showed that J14, a conformational 
restricted peptide antigen which is genetically restricted, 
offered protection against GAS infection when conju- 
gated to diphtheria toxoid. However, J14 lost its immu- 
nogenicity when it was expressed with a fusion partner in 
a recombinant construct [10]. We attributed this to the 
loss of secondary conformation of the peptide in the 
context of its fusion partner. To solve this problem, we 
redesigned the antigen to contain two moieties of J14 
[10]. In the present study, this new vaccine candidate, 
called JJo, is shown to stimulate a JJo-specific humoral 
response in mice representing different genetic back- 
grounds (Balb/c, C3HeJ and B10BR). Titres against JJo 
in all the three genetic background are similar (mean titre 
25600; Figure 1(a)). 
In a separate experiment, sera from these mice reacted 
with the parent peptide J14 (data not shown). These 
results confirm our earlier results obtained with Balb/c 
[10]. Taken together, our results show that the immune 
response of the recombinant JJo is not genetically res- 
tricted and hence unlike short B cell epitopes which need 
help with heterologous T cell epitopes (such as diphthe- 
ria toxoid), recombinant JJo on its own is immunogenic 
without additional T-cell help.  
3.2. Binding Characteristics of JJo Antibodies to  
GAS Isolates 
In order to test that JJo antibodies bind to M protein on 
the GAS cell surface, we used several independent ap- 
proaches. Firstly, the immune sera reacted with whole 
cells of two representative strains representatives of pre- 
valent Indian M-types (C28 and Mu3) in a whole-cell  
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Figure 1. Comparison of immunogenicity of JJo in mice 
with different genetic backgrounds. (a) Microtiter plates 
were coated with recombinant JJo (500 ng/well); (b) Micro- 
titer plates coated with Mu3 or C28 GAS isolates. For whole 
cell ELISA, the GAS isolates were grown overnight in THB 
media at 37˚C. The streptococci cells washed and resus- 
pended in PBS to an OD600 of 0.4. Diluted cells (100 μl) 
were aliquoted to each well of the microtitre plate and in- 
cubated at 37˚C for 30 min. Non-adherent bacteria were 
removed by washing and standard ELISA protocol was 
followed. 
 
ELISA experiment (Figure 1(b)) suggesting that the cell 
surface antigen in its native form is recognized by JJo 
antibodies. The binding characteristics in both these 
strains are similar. We then extended this study by prob- 
ing a broader set of Indian strains with IFA (Figure 2(a)) 
and flow cytometry (FACS) (Figure 2(b)). The Results 
of both IFA and FACS (Table 1) confirmed binding of 
JJo specific antibodies to the surface of GAS cells of 
diverse M types. All GAS strains typically contained 
within their last C-terminal repeat M-specific sequences 
corresponding to either J14 or J14.1 [18]. Anti-J14 antis- 
era cross react with J14 and J14.1 and vice versa [19]. 
Therefore it is not surprising that anti-JJo cross-reacted  
 
(a) 
 
 
(b) 
Figure 2. Immunofluorescent microscopy and flow cyto- 
metric analysis of representative Indian GAS isolates. (a) 
Immunofluorescent micrographs and corresponding bright 
field images of GAS strains Mu3 (left panel), C28 (middle 
panel) and JRS145 (right panel) probed with JJo specific 
antibodies. JJo antibodies bound strongly to Indian GAS 
isolates Mu3 and C28, however no binding was observed to 
M-negative JRS145. Sham control sera did not bind to ei- 
ther GAS strain (data not shown); (b) Flow cytometric 
analysis of GAS isolates Mu3 (left graph) and C28 (right 
graph) probed with JJo or sham control antisera. A small 
shift to the right was observed when cells were incubated 
with sham control sera indicating a low level of non-specific 
binding. However, a large shift to the right was observed 
following incubation with anti-JJo antibody. The fluores- 
cent peak for the bacterial cell control was at far right, in- 
dicative of no antibody binding. For each sample, data for 
10,000 events were analyzed. 
 
with all the GAS isolates tested. 
While JJo antibodies bound to all of the GAS strains 
tested the levels of binding as measured by the signal 
intensity did vary somewhat from strain to strain. In 
addition, for some isolates there was poor correlation 
between the fluorescence intensity observed in IFA and 
the mean fluorescence intensity (MFI) as determined   
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Table 1. Summary of the strains tested in this study and their reactivity of JJo antibodies as determined by immunofluo- 
rescence and flow cytometry. 
Strain Source emm type# IFA intensity* Cells that bound antibody (%) MFI 
Mu3 Mumbai 81.2 +++ 92.3 275 
Mu167 Mumbai 12.8 +++ 91.8 213 
Mu196 Mumbai 34.8 +++ 69.5 111 
Mu199 Mumbai 4.4 ++ 33.3 68.2 
Mu224 Mumbai 87.0 +++ 95.7 118 
V12 Vellore 25.1 ++ 58.5 76 
V18 Vellore 4.5 ++ 56.1 108 
V24 Vellore 1.2-2 +++ 86.8 133.4 
V25 Vellore 86.2 +++ 95.7 118 
V54 Vellore 118.0 + 86.4 216 
V75 Vellore 42.1 +++ 88.2 47.2 
C23 Chennai 77.0 +++ 78.2 41.5 
C28 Chennai 63.3 +++ 83.7 163.1 
*Positive control was an M1 strain which gave in intensity of ++++. JRS145, an M-negative strain, and sham immune sera were negative controls; #Assignment 
of emm types based on www.cdc.gov/ncidod/biotech/strep/strepindex.htm. 
 
by FACS. Taken together it is clear that JJo antibodies 
react with M proteins from all the GAS strains tested. 
However, native M protein on the surface of cells may 
not be equally accessible for binding by the JJo anti- 
bodies. This is not unexpected as differences in capsular 
thickness [20], the number of CRRs [21], the level of 
expression of M protein or loss of the M protein on 
surface [22] have been described and could account for 
this observed inequality. In the IFA, JJo antiserum did 
not react with M-negative GAS strain JRS145 (Figure 
2(a)), which suggests that the anti-JJo antibody speci- 
fically reacts with M protein on the cell surface. 
3.3. JJo Antibodies Opsonize GAS 
Anti-phagocytic function is the main biological attribute 
of the M protein. To test whether JJo antibodies, like 
antibodies to the parent J14 molecule, are capable of 
opsonizing GAS strain C28 or PL1 was incubated with 
human blood in an indirect bactericidal assay. We opted 
to use Australian blood donors because we found it 
difficult to identify suitable donors (whose blood sup- 
ports growth of GAS) in our cohort of volunteers from a 
region highly endemic for GAS infection (probably 
because of natural antibodies to GAS). We also did not 
find suitable donors for bactericidal assays for Mu3 
which was the strain passaged for GAS challenge model. 
As shown in Table 2, antibodies raised in Quackenbush 
and B10BR mice to recombinant JJo or peptide J14 
(conjugated to diphtheria toxoid) are opsonic to PL1 
whereas sham immunized mice sera aren’t. The results 
were also reproducible with C28 when tested against a 
suitable donor blood from Australia (Table 2). 
3.4. JJo Antibodies Protect Mice against GAS  
Infection 
In the mouse challenge model for protection against sys- 
temic GAS infection, it is necessary initially to passage 
GAS strains through mice for several cycles to increase 
their virulence in this model [23]. We succeeded in doing 
this for one Indian GAS strain, Mu3. If indeed the reac- 
tive epitope for JJo antiserum is abundantly accessible in 
a strain, as for instance in Mu3, we expected that the 
antiserum to be protective against the strain in a mouse- 
challenge experiment. To test this, we immunized C3HeJ 
mice with JJo. The immunized mice were challenged 
with minimal lethal dose of mouse-passaged Mu3. As 
predicted, the JJo immunized mice survived the chal- 
lenge significantly better than sham-immunized mice (p 
= 0.019; Log-ranked Mantel-Cox test; Figure 3). These 
results confirm that JJo antibodies are protective against 
GAS infection with an endemic Indian isolate. 
4. Discussion 
Our present study clearly suggests broad reactivity of JJo     
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Table 2. In vitro bactericidal activity of antibodies raised against JJo in mice with different genetic backgrounds. 
*Each sample was tested in duplicate; tube 1 and tube 2, and each tube plated in duplicate. The mean CFU counts from the two plates for each sample were 
subsequently calculated. For the PBS sample, the mean CFU counts from tube 1 and tube 2 (4 plates in total) were calculated; †% reduction in mean CFU was 
calculated as: 1 – [mean CFUs in the presence of immune mouse sera/mean CFUs in the presence of sera from PBS immunised mice] × 100. 
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Figure 3. Survival curves for JJo immunized C3HeJ mice 
following intraperitoneal challenge with mouse-passaged 
Mu3 GAS strain. The percentage survival determined up to 
10 days following challenge. Mice immunized with JJo 
(solid line) survived better than control mice (dashed line; p 
= 0.0190). Ten mice were included in each group. 
 
antibodies against variety of GAS strains, and the func- 
tionality of these antibodies tested against a sub-set of 
these isolates using in-direct bactericidal assay and a 
mouse model of systemic GAS infection. While our 
study shows the overall coverage of strains for JJo-based 
vaccine is good, to avoid possible escape of strains from 
JJo antibody mediated clearance due to poor accessibility, 
there is strong argument for a polyepitope vaccine 
approach for GAS. In a similar attempt to make recom- 
binant vaccine construct with broad coverage, Penfound 
et al. [11] recently combined J14 with other N-terminal 
epitopes from 6 M types. However, they consistently 
found that J14 was not immunogenic in such polyepitope 
constructs. Earlier we too demonstrated [10] conforma- 
tional stabilization of J14 was required for appropriate 
immune response in a recombinant construct. We showed 
that the JJo derivative of J14 when expressed as a re- 
combinant fusion protein elicited J14-specific immune 
response. These experiments confirmed earlier work [24] 
suggesting requirement for conformational stability for 
protective immune response. Our current work advocates 
that JJo replace J14 in all future recombinant polyepitope 
vaccine designs. 
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